New Triple-Threat drug cocktail tested for Tough-to-Treat leukemias
NCT ID NCT06401603
Summary
This early-phase study aims to find safe and effective doses of a three-drug combination (decitabine, lisaftoclax, and olverembatinib) for adults with advanced forms of chronic myeloid leukemia (CML) or a specific type of acute myeloid leukemia (AML). The goal is to control the disease and improve outcomes for patients who have not responded well to prior standard treatments. Researchers will closely monitor safety and how well the combination works to reduce cancer burden.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CHRONIC MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.